Three-Year Follow-Up From Phase 3 TRANSFORM: Study Overview and Key Efficacy Data

Experts discuss the 3-year follow-up from the phase 3 TRANSFORM study, providing an overview of the study and key efficacy data.

EP: 1.Brief Overview of Current Treatment Landscape and Unmet Needs in R/R Large B-Cell Lymphoma

Now Viewing

EP: 2.Three-Year Follow-Up From Phase 3 TRANSFORM: Study Overview and Key Efficacy Data

EP: 3.Long-Term Efficacy and Real-World Outcomes With Liso-cel

EP: 4.Patient Selection and Timing Considerations for CAR T Therapy

EP: 5.Impact of Manufacturing and Treatment Timing on Patient Outcomes for CAR T in R/R LBCL

EP: 6.Clinical Features and Risk Factors: Navigating ASCT vs CAR T Therapy Decisions in R/R LBCL

EP: 7.TRANSFORM Safety Summary

EP: 8.Safety Management and Monitoring Protocols for Liso-cel

EP: 9.Future Directions and Key Insights in LBCL Treatment

Recent Videos